Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2369 publications

Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure.

Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure.

Journal: Acta gastro-enterologica Belgica
Published: October 13, 2025

Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study.

Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study.

Journal: Journal of Crohn's & colitis
Published: October 13, 2025

No post-infusion reactions after infliximab or vedolizumab.

No post-infusion reactions after infliximab or vedolizumab.

Journal: Danish medical journal
Published: October 10, 2025

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission.

Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remission.

Journal: Revista espanola de enfermedades digestivas
Published: September 29, 2025

Predictive value of the Chinese Visceral Adiposity Index for disease activity and vedolizumab response in ulcerative colitis.

Predictive value of the Chinese Visceral Adiposity Index for disease activity and vedolizumab response in ulcerative colitis.

Journal: Nutricion hospitalaria
Published: September 29, 2025

Correction: Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review.

Correction: Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review.

Journal: Cureus
Published: September 26, 2025

Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data study.

Ustekinumab versus vedolizumab and ustekinumab versus tumor necrosis factor alpha agent infectious adverse effects in patients with ulcerative colitis, a real-world data study.

Journal: Expert opinion on pharmacotherapy
Published: September 18, 2025

Comparison of utilization and total medicare fee-for-service expenditures for subcutaneous versus intravenous versions of a select group of therapies.

Comparison of utilization and total medicare fee-for-service expenditures for subcutaneous versus intravenous versions of a select group of therapies.

Journal: Journal of medical economics
Published: September 12, 2025

Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.

Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.

Journal: Journal of Crohn's & colitis
Published: September 10, 2025

Blood proteomic signatures associated with disease activity in Inflammatory Bowel Diseases.

Blood proteomic signatures associated with disease activity in Inflammatory Bowel Diseases.

Journal: Journal of Crohn's & colitis
Published: September 08, 2025

Distinct B Cell Subsets Changes as Potential Biomarkers of Response to Biologic Therapy in Crohn's Disease.

Distinct B Cell Subsets Changes as Potential Biomarkers of Response to Biologic Therapy in Crohn's Disease.

Journal: International journal of molecular sciences
Published: September 05, 2025

Combination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review.

Combination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review.

Journal: Journal of Crohn's & colitis
Published: September 03, 2025
Showing 1-12 of 2,369

Last Updated: 10/31/2025